A novel mTOR inhibitor is efficacious in a murine model of colitis

Authors:
  • RGRavindra D. Gupte
    Ravindra D. Gupte
  • SDShruta D. Dadarkar
    Shruta D. Dadarkar
  • MJMahesh G. Jadhav
    Mahesh G. Jadhav
  • ATAditi A. Tannu
    Aditi A. Tannu
  • PBPooja Bhatt
    Pooja Bhatt
  • DBDimple R. Bhatia
    Dimple R. Bhatia
  • NDNikesh K. Desai
    Nikesh K. Desai
  • VDVijaykumar Deore
    Vijaykumar Deore
  • NYNilambari Yewalkar
    Nilambari Yewalkar
  • RVRam A. Vishwakarma
    Ram A. Vishwakarma
  • SSSomesh Sharma
    Somesh Sharma

Abstract
Ulcerative colitis is an autoimmune-inflammatory disease characterized by increased proliferation of colonic epithelial cells, dysregulation of signal transduction pathways, elevated mucosal T cell activation, increased production of proinflammatory cytokines, and enhanced leukocyte infiltration into colonic interstitium. Several compounds that possess antiproliferative properties and/or inhibit cytokine production exhibit a therapeutic effect in murine models of colitis. Mammalian target of rapamycin (mTOR), a protein kinase regulating cell proliferation, is implicated in colon carcinogenesis. In this study, we report that a novel haloacyl aminopyridine-based molecule (P2281) is a mTOR inhibitor and is efficacious in a murine model of human colitis. In vitro studies using Western blot analysis and cell-based ELISA assays showed that P2281 inhibits mTOR activity in colon cancer cells. In vitro and in vivo assays of proinflammatory cytokine production revealed that P2281 diminishes induced IFN-γ production but not TNF-α production, indicating preferential inhibitory effects of P2281 on T cell function. In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR. Collectively, these results provide direct evidence that P2281, a novel mTOR inhibitor, suppresses DSS-induced colitis by inhibiting T cell function and is a potential therapeutic for colitis. Given that compounds with anticancer activity show promising anti-inflammatory efficacy, our findings reinforce the cross-therapeutic functionality of potential drugs.

This publication has 58 references indexed in Scilit: